R. C.
- Country
- Spain
- Department
- Hematology
Research Overview
- HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
- HOVON 156 AML: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.
Data & Insights
Has run more than one trial at 104 of 168 partner sites.
Specializations
Hematologic Malignancies
R. Coll leads investigations into aggressive blood cancers, emphasizing therapeutic strategies for Acute myeloid leukemia, Chronic lymphocytic leukemia, and Multiple myeloma.
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Multiple myeloma
- Diffuse large B-cell lymphoma
- Mantle cell lymphoma
Efforts integrate novel agents and biomarker‑driven approaches to improve remission durability.
Stem Cell Transplantation & Graft‑versus‑Host Disease
The investigator’s work at the Hospital Universitari De Girona includes optimization of allogeneic transplantation and management of Acute graft‑versus‑host disease.
- Allogeneic hematopoietic stem cell transplant
- Acute graft‑versus‑host disease
- Chronic graft‑versus‑host disease
- Transplant conditioning regimens
- Post‑transplant immune reconstitution
Research aims to reduce transplant‑related toxicity while preserving graft efficacy.
Myelodysplastic Syndromes & Myeloproliferative Neoplasms
Focused on clonal bone‑marrow disorders, R. Coll studies risk stratification and targeted therapy for Myelodysplastic syndrome and Myeloproliferative neoplasms.
- Myelodysplastic syndrome
- Myeloproliferative neoplasm
- High‑risk MDS
- JAK inhibitor‑resistant myelofibrosis
- IDH1‑mutated AML
Clinical programs evaluate hypomethylating agents and emerging molecular inhibitors.
Lymphoid Oncology and Immunotherapy
Investigations extend to B‑cell and T‑cell malignancies, exploring immunotherapeutic options for Follicular lymphoma and Peripheral T‑cell lymphoma.
- Follicular lymphoma
- Peripheral T‑cell lymphoma
- CAR‑T cell therapy
- Bispecific antibodies
- Checkpoint inhibition
Studies assess response durability and safety in relapsed or refractory settings.
Translational Research & Biomarker Development
R. Coll integrates genomic profiling to identify predictive markers across hematologic cancers, supporting precision medicine.
- Next‑generation sequencing
- Minimal residual disease
- Mutational profiling
- Cytogenetic risk assessment
- Biomarker‑guided therapy
Data are generated in collaboration with the Institut Català d'Oncologia.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.